Eurofins, AmpTec to Co-market Synthetic RNAs | GenomeWeb

NEW YORK (GenomeWeb) — Eurofins Genomics and AmpTec have agreed to non-exclusively co-market AmptTec's IVT-RNAs globally under a deal announced today.

The co-marketing agreement covers in vitro transcribed single-stranded, double-stranded, and functional synthetic mRNAs that can be used in a variety of applications including in vitro diagnostics of pathogens, rare mutation detection, and companion diagnostics, Eurofins said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: new chromatin imaging approach, and more.

University of Wisconsin researchers uncover a mutation linked to Mauriac syndrome, which affects some children with type 1 diabetes.

Theranos has hired executives to oversee compliance and regulatory issues, the Wall Street Journal reports.

Chinese researchers to embark on a trial using a CRISPR/Cas9-based immunotherapy next month, Nature News reports.